Tyler Jacks

Tyler Jacks is a Fellow at the Massachusetts Institute of Technology, affiliated with the Department of Biology. His research focuses on the genetic events contributing to cancer development, particularly through the creation of genetically engineered mouse models (GEMMs) to study tumor initiation, progression, and response to therapies. His work also explores tumor immunology, including interactions between the immune system and cancer. Jacks is associated with the Koch Institute for Integrative Cancer Research and holds the Daniel K. Ludwig Scholar for Cancer Research title. His research has involved the development of models with mutations in tumor suppressor genes, oncogenes, and genes related to DNA repair and epigenetic control. He is also engaged in tumor immunology research, examining immune system interactions with cancer.

Tyler Jacks is a researcher whose work focuses on the molecular mechanisms underlying cancer development and progression. His research explores the role of p53, microRNAs, and chromatin structure in tumor biology. Key areas include the regulation of apoptosis, cell cycle checkpoints, and the function of non-coding RNAs in cancer. His studies have investigated how genetic mutations, such as those in p53 and KRAS, contribute to oncogenesis and how these pathways can be targeted for therapeutic intervention. Jacks has also examined the impact of hypoxia and microRNA dysregulation on tumor progression and the potential of lung and pancreatic cancer models for early detection.